학술논문
42136 Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials
Document Type
Abstract
Author
Source
In Journal of the American Academy of Dermatology September 2023 89(3) Supplement:AB188-AB188
Subject
Language
ISSN
0190-9622